Fenimore Christopher R.'s Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 20, 2026
- Accession no.
- 0001697422-26-000002
- Filed
- Aug 20, 2026, 4:01 PM ET
- Trade date
- Aug 18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fenimore Christopher R.CIK 0001697422 | Officer (EVP Finance CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Common Stock | MOption exerciseAcquired | +6,283 | $381.92 | +$2,399,603.36 | 24,583 | Direct | |
| Aug 18, 2026 | Common Stock | FTax withholdingDisposed | −4,599 | $813.47 | −$3,741,148.53 | 19,984 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Common Stock | MOption exerciseDisposed | −6,283 | $0.00 | $0 | 6,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.